Shelly Lynn Gray

Dr. Shelly Lynn Gray

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
SGShelly Lynn Gray
Shelly Lynn Gray
MAMelissa L. Anderson
Melissa L. Anderson
SDSascha Dublin
Sascha Dublin
JHJoseph T. Hanlon
Joseph T. Hanlon
RHRebecca Hubbard
Rebecca Hubbard
ELEric B Larson
Eric B Larson
Medications with anticholinergic activity are used widely by older adults for diverse conditions, such as overactive bladder, seasonal allergies, and depression. Some anticholinergics achieve the intended therapeutic outcome by blocking the effect of acetylcholine at the muscarinic receptor within specific organ systems (eg, antispasmodics for the gastrointestinal tract, antimuscarinics for the bladder, and antiparkinsonians). However, other medications have unintended anticholinergic effects that are not the primary therapeutic activity (eg, first-generation antihistamines, tricyclic antidepressants, and certain antipsychotics).

10 May 2010 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
SGShelly Lynn Gray
Shelly Lynn Gray
ALAndrea Z. LaCroix
Andrea Z. LaCroix
JLJoseph Larson
Joseph Larson
JRJohn Robbins
John Robbins
JCJane A Cauley
Jane A Cauley
ZCZhao Chen
Zhao Chen
Proton pump inhibitors (PPIs) are the most potent gastric acid–suppressing medications available. These agents have dramatically transformed the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD). Millions of PPI prescriptions are dispensed annually in the United States and worldwide, with long-term therapy needed by many to treat the chronic symptoms of GERD.1,2 Omeprazole was ranked 15th of all generic prescriptions, and esomeprazole ranked second of all brand-name prescriptions dispensed in the United States during 2008.1,2

2 February 2016 in BMJ
Verified
Journal Article
Open access
PDF file
SGShelly Lynn Gray
Shelly Lynn Gray
SDSascha Dublin
Sascha Dublin
OYOnchee Yu
Onchee Yu
RWRod Walker
Rod Walker
MAMelissa Anderson
Melissa Anderson
ELEric B Larson
Eric B Larson
Objective To determine whether higher cumulative use of benzodiazepines is associated with a higher risk of dementia or more rapid cognitive decline. Design Prospective population based cohort. Setting Integrated healthcare delivery system, Seattle, Washington. Participants 3434 participants aged ≥65 without dementia at study entry. There were two rounds of recruitment (1994-96 and 2000-03) followed by continuous enrollment beginning in 2004. Main outcomes measures The cognitive abilities screening instrument (CASI) was administered every two years to screen for dementia and was used to examine cognitive trajectory. Incident dementia and Alzheimer’s disease were determined with standard diagnostic criteria. Benzodiazepine exposure was defined from computerized pharmacy data and consisted of the total standardized daily doses (TSDDs) dispensed over a 10 year period (a rolling window that moved forward in time during follow-up). The most recent year was excluded because of possible use for prodromal symptoms. Multivariable Cox proportional hazard models were used to examine time varying use of benzodiazepine and dementia risk. Analyses of cognitive trajectory used linear regression models with generalized estimating equations. Results Over a mean follow-up of 7.3 years, 797 participants (23.2%) developed dementia, of whom 637 developed Alzheimer’s disease. For dementia, the adjusted hazard ratios associated with cumulative benzodiazepine use compared with non-use were 1.25 (95% confidence interval 1.03 to 1.51) for 1-30 TSDDs; 1.31 (1.00 to 1.71) for 31-120 TSDDs; and 1.07 (0.82 to 1.39) for ≥121 TSDDs. Results were similar for Alzheimer’s disease. Higher benzodiazepine use was not associated with more rapid cognitive decline. Conclusion The risk of dementia is slightly higher in people with minimal exposure to benzodiazepines but not with the highest level of exposure. These results do not support a causal association between benzodiazepine use and dementia.

18 February 2013 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
SGShelly Lynn Gray
Shelly Lynn Gray
MAMelissa L. Anderson
Melissa L. Anderson
RHRebecca A. Hubbard
Rebecca A. Hubbard
ALAndrea LaCroix
Andrea LaCroix
PCPaul Crane
Paul Crane
ELEric B. Larson
Eric B. Larson
We sought to examine whether frailty is associated with dementia, Alzheimer’s disease (AD), and non-AD dementia risk. This is a prospective population-based cohort derived from an integrated health maintenance organization. The sample consisted of 2,619 participants aged 65 and older without dementia at baseline followed from 1994 to 2010. Frailty was defined as having at least 3 of the following criteria: weakness (grip strength), slowness (walking speed), weight loss, low physical activity, and self-reported exhaustion. Follow-up occurred every 2 years to identify incident dementia, possible or probable AD, and non-AD dementia using standard research criteria. Covariates came from self-report and study measures. We used adjusted Cox proportional hazards models to examine the association between frailty and each outcome. Over a mean follow-up of 6.5 years, 521 participants developed dementia (of which 448 developed AD). In the model adjusted for age, sex, education, and race, the hazard ratio for frailty was 1.78 (95% confidence interval [CI] 1.32–2.40). In the fully adjusted models, the hazard ratio for frailty was 1.20 for all-cause dementia (95% CI 0.85–1.69), 1.08 for AD (95% CI 0.74–1.57), and 2.57 for non-AD dementia (95% CI 1.08–6.11). For all-cause dementia, we found an interaction between baseline cognitive score and frailty (p = .02); hazard ratio for frailty was 1.78 for those with higher global cognition (95% CI 1.14–2.78) and 0.79 for those with lower global cognition (95% CI 0.50–1.26). Frailty was associated with dementia when adjusting only for demographic variables but not in the fully adjusted model. Frailty was associated with higher risk of developing non-AD dementia but not AD. Although frailty was not associated with all-cause dementia in the entire sample, an association did exist in participants with higher cognitive scores. Mechanisms underlying these associations remain to be elucidated.

1 January 1999 in Drug Safety
Verified
Journal Article
Closed access
PDF file
SGShelly Lynn Gray
Shelly Lynn Gray
KLKatie V. Lai
Katie V. Lai
ELEric B. Larson
Eric B. Larson

8 December 2005 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
SGShelly Lynn Gray
Shelly Lynn Gray
ALAndrea Z. LaCroix
Andrea Z. LaCroix
JHJoseph T. Hanlon
Joseph T. Hanlon
BPBrenda W. J. H. Penninx
Brenda W. J. H. Penninx
DBDavid K. Blough
David K. Blough
DBDave M. Buchner
Dave M. Buchner